Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX)
CUSIP: 45720N103
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 14,560,641
- Total 13F shares
- 10,497,334
- Share change
- +60,929
- Total reported value
- $353,550,847
- Put/Call ratio
- 254%
- Price per share
- $33.68
- Number of holders
- 101
- Value change
- +$6,764,063
- Number of buys
- 46
- Number of sells
- 46
Quarterly Holders Quick Answers
What is CUSIP 45720N103?
CUSIP 45720N103 identifies INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45720N103:
Top shareholders of INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
12%
|
1,787,705
|
$25,510,550 | — | 30 Jun 2025 | |
| Sanofi |
13F
|
Company |
8%
|
1,157,926
|
$16,523,604 | — | 30 Jun 2025 | |
| Mark P. Lappe |
3/4/5
13D/G
|
Chief Executive Officer, Director · Mark Lappe |
6.4%
from 13D/G
|
1,225,413
mixed-class rows
|
$15,852,324 | — | 12 Sep 2024 | |
| Jon Faiz Kayyem |
3/4/5
13D/G
|
Director |
7.9%
from 13D/G
|
1,074,046
mixed-class rows
|
$15,030,087 | — | 28 May 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
6.7%
|
977,892
|
$13,954,518 | — | 30 Jun 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
6%
|
871,759
|
$12,440,001 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5%
|
728,744
|
$10,399,176 | — | 30 Jun 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
4.9%
|
708,678
|
$10,112,835 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
4.6%
|
662,868
|
$9,459,126 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
598,448
|
$8,539,853 | — | 30 Jun 2025 | |
| Brendan P. Eckelman |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
648,888
mixed-class rows
|
$6,127,372 | — | 29 May 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.9%
|
275,778
|
$3,935,352 | — | 30 Jun 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
1.7%
|
244,261
|
$3,485,604 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
225,955
|
$3,225,084 | — | 30 Jun 2025 | |
| Douglas G. Forsyth |
3/4/5
|
Director |
—
mixed-class rows
|
239,564
mixed-class rows
|
$3,159,615 | — | 28 May 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.4%
|
204,959
|
$2,924,765 | — | 30 Jun 2025 | |
| Caption Management, LLC |
13F
|
Company |
1.4%
|
199,508
|
$2,846,979 | — | 30 Jun 2025 | |
| Slotnik Capital, LLC |
13F
|
Company |
1.3%
|
184,171
|
$2,628,120 | — | 30 Jun 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.2%
|
177,318
|
$2,530,328 | — | 30 Jun 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.1%
|
154,790
|
$2,208,853 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.82%
|
120,124
|
$1,713,000 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.67%
|
97,685
|
$1,393,964 | — | 30 Jun 2025 | |
| Groupe la Francaise |
13F
|
Individual |
0.52%
|
75,932
|
$1,083,550 | — | 30 Jun 2025 | |
| CREDIT INDUSTRIEL ET COMMERCIAL |
13F
|
Individual |
0.44%
|
64,217
|
$916,377 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.35%
|
50,478
|
$720,322 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.32%
|
45,984
|
$656,192 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.29%
|
42,122
|
$601,081 | — | 30 Jun 2025 | |
| Laird Norton Wetherby Wealth Management, LLC |
13F
|
Company |
0.28%
|
40,656
|
$580,162 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.27%
|
39,071
|
$557,538 | — | 30 Jun 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.25%
|
36,206
|
$516,660 | — | 30 Jun 2025 | |
| Murchinson Ltd. |
13F
|
Company |
0.23%
|
33,790
|
$482,183 | — | 30 Jun 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.22%
|
32,110
|
$458,210 | — | 30 Jun 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.21%
|
29,993
|
$427,999 | — | 30 Jun 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
28,230
|
$402,842 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
27,808
|
$396,821 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
27,793
|
$396,606 | — | 30 Jun 2025 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
0.18%
|
26,834
|
$382,921 | — | 30 Jun 2025 | |
| Meridian Wealth Advisors, LLC |
13F
|
Company |
0.17%
|
25,000
|
$356,750 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.16%
|
23,073
|
$329,252 | — | 30 Jun 2025 | |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management |
13F
|
Company |
0.16%
|
22,584
|
$322,274 | — | 30 Jun 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.15%
|
22,170
|
$316,366 | — | 30 Jun 2025 | |
| Kristiina Vuori MD |
3/4/5
|
Director |
—
mixed-class rows
|
35,443
mixed-class rows
|
$306,645 | — | 28 May 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.15%
|
21,214
|
$302,724 | — | 30 Jun 2025 | |
| Yakira Capital Management, Inc. |
13F
|
Company |
0.15%
|
21,118
|
$301,354 | — | 30 Jun 2025 | |
| JBF Capital, Inc. |
13F
|
Company |
0.14%
|
20,949
|
$298,942 | — | 30 Jun 2025 | |
| Corient Private Wealth LLC |
13F
|
Company |
0.14%
|
20,455
|
$291,893 | — | 30 Jun 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.14%
|
20,420
|
$291,393 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.14%
|
19,886
|
$283,773 | — | 30 Jun 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.14%
|
19,783
|
$282,000 | — | 30 Jun 2025 | |
| Arbiter Partners Capital Management LLC |
13F
|
Company |
0.14%
|
19,759
|
$281,960 | — | 30 Jun 2025 |
Institutional Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) as of Q3 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.